Novo Nordisk in $1.3 billion deal to buy hypertension drug
Send a link to a friend
[October 17, 2023]
COPENHAGEN (Reuters) - Novo Nordisk has agreed to buy ocedurenone,
a drug for uncontrolled hypertension with potential application in
cardiovascular and kidney disease, from KBP Biosciences for up to $1.3
billion, the Danish drugmaker said on Monday.
"This deal is closely aligned with our strategic focus on expanding from
our core in diabetes into other serious chronic diseases, including
through novel drug modalities," Novo said in a statement.
The acquisition is expected to close before the end of this year, Novo
said, adding that the deal will not impact its operating profit outlook
for 2023.
Ocedurenone is an orally administered drug that is currently examined in
the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension
and advanced chronic kidney disease, Novo said.
[to top of second column]
|
![](../images/101723PIX/health22.jpg)
Flags with the Novo Nordisk logo flutter outside their Danish
company's offices in Copenhagen, Denmark, September 26, 2023.
REUTERS/Tom Little/File Photo
![](http://archives.lincolndailynews.com/2023/Oct/17/images/ads/current/fcs_funeral_lda_border_04029022.png) (Reporting by Louise Breusch
Rasmussen, editing by Terje Solsvik)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |